Kenneth Merrell, MD, MS

Mayo Clinic Alix School of Medicine
Rochester, MN

Disclosures:

• Employment: Mayo Clinic:MD:Employee;Mayo Clinic:Physician:Employee
• Compensation: Pfizer:Role Topic Description-End Date: 2028 ;AstraZeneca: Research Grants, Research Funding, Research Salary Support,Research Role Description Topic-End Date: 2025 ;Galera: Research Grants, Research Funding, Research Salary Support,Research Role Description Topic-End Date: 2024 ;Novartis: Research Grants, Research Funding, Research Salary Support,Research Role Description Topic-End Date: 2026 ;Varian: Research Grants, Research Funding, Research Salary Support,Research Role Description Topic-End Date: 2028 ;Pfizer:Role Topic Description-End Date: 2028 ;AstraZeneca: Research Grants, Research Funding, Research Salary Support,Research Role Description Topic-End Date: 2025 ;Galera: Research Grants, Research Funding, Research Salary Support,Research Role Description Topic-End Date: 2024 ;Novartis: Research Grants, Research Funding, Research Salary Support,Research Role Description Topic-End Date: 2026 ;Varian: Research Grants, Research Funding, Research Salary Support,Research Role Descript
• Ownership: none
• Leadership: GACCF:Chairman;Global Access to Cancer Care Foundation:Chairman

Presentation(s):

• 2 - A Prospective, Phase II Study of ¹⁷⁷Lu-Dotatate in Patients with Surgery- and Radiation-Refractory Meningioma: Results of the WHO Grade II/III Cohort

  Sunday, September 29, 2024
  1:00 PM – 1:10 PM ET

• 353 - Safety and Efficacy Results of a Phase II Clinical Trial Evaluating Moderately-Hypofractionated Chemoradiotherapy for Pancreatic Ductal Adenocarcinoma

  Wednesday, October 2, 2024
  10:50 AM – 11:00 AM ET